🔎 Trials Near Me

Hjem › Burkitts lymfom › Texas › Dallas

Burkitts lymfom kliniske forsøg i Dallas, TX

7 studier for Burkitts lymfom søger deltagere på steder i og omkring Dallas (inden for ca. 30 miles). Åbn et studie for at se, hvem der kan deltage, og hvordan man kontakter studieteamet.

Officiel studietekst (engelsk)

Rekrutterer til et studie her? Få det vist øverst på siden — $99 i 30 dage →

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

RekruttererFase 2
  • Medical City Dallas Hospital, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
365 Days · Alle køn · Opdateret 25. sep. 2026 · NCT06317662

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

RekruttererFase 2
  • Medical City Dallas Hospital, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
Alder 1 til 30 · Alle køn · Opdateret 1. sep. 2026 · NCT04546399

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

RekruttererFase 3
  • Medical City Dallas Hospital, Dallas
  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
365 Days – 25 Years · Alle køn · Opdateret 25. aug. 2026 · NCT03959085

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

RekruttererFase 2
  • University of Texas, Southwestern, Dallas
Alder 7 til 25 · Alle køn · Opdateret 19. aug. 2026 · NCT05082519

Study of SGR-1505 in Mature B-Cell Neoplasms

RekruttererFase 1
  • University of Texas Southwestern, Dallas
Alder 18 og opefter · Alle køn · Opdateret 13. feb. 2026 · NCT05544019

Burkitts lymfom forsøg i andre byer

Andre studier i Dallas

Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.